How does Bacitracin/Polymyxin B kill bacteria? Learn how this combination antibiotic works in plain English, how fast it acts, and what makes it different.
Bacitracin/Polymyxin B is a combination antibiotic ointment that kills bacteria using a "one-two punch" strategy. Each ingredient targets a different part of the bacterial cell, making it harder for bacteria to survive or develop resistance. Here's how it works — no biology degree required.
To understand how Bacitracin/Polymyxin B works, it helps to think of a bacterium as a tiny building with two key structures: a wall (the rigid outer shell) and a membrane (the flexible inner lining).
Bacitracin targets the bacterial cell wall. Bacteria constantly need to rebuild and maintain their cell walls to survive and multiply. Think of it like a brick wall that needs constant repairs.
Bacitracin works by blocking a molecule called a phospholipid carrier — essentially the "delivery truck" that brings new building materials to the cell wall construction site. Without this carrier, the bacterium can't make new wall material (called peptidoglycan). The wall weakens, develops holes, and the bacterium eventually bursts and dies.
Bacitracin is particularly effective against gram-positive bacteria — organisms like Staphylococcus aureus and Streptococcus species that are common causes of eye and skin infections.
While Bacitracin attacks the wall, Polymyxin B goes after the bacterial cell membrane — the inner lining that holds everything inside the cell together.
Polymyxin B is a positively charged molecule that's attracted to the negatively charged components (called lipopolysaccharides) on the outer surface of certain bacteria. When it binds to these components, it punches holes in the membrane, causing the cell's contents to leak out. Imagine poking holes in a water balloon — everything inside spills out, and the balloon (the bacterium) collapses.
Polymyxin B is especially effective against gram-negative bacteria — organisms like Pseudomonas, E. coli, and Haemophilus species.
Here's what makes this combination smart: Bacitracin handles gram-positive bacteria, and Polymyxin B handles gram-negative bacteria. Together, they provide broad-spectrum coverage — meaning they can fight a wide range of bacterial species.
This is important because when your eye is infected, your doctor may not know exactly which type of bacteria is causing the problem. By using a combination that covers both major groups, the medication can start working right away without waiting for lab results.
It's like having both a deadbolt and a chain lock on your door — each one provides a different kind of protection, and together they're more effective than either one alone.
Bacitracin/Polymyxin B starts killing bacteria on contact when applied to the infected area. However, you won't see full results immediately:
If you don't notice any improvement after 3 days, contact your doctor. The infection may be caused by bacteria that are resistant to these antibiotics, or it may not be bacterial at all (viral and fungal infections don't respond to Bacitracin/Polymyxin B).
When applied as an ophthalmic ointment, Bacitracin/Polymyxin B stays on the surface of the eye for several hours. This is actually one advantage of the ointment form over eye drops — the ointment has a longer contact time, meaning it stays in contact with the infected area longer.
That's why the typical dosing schedule is every 3 to 4 hours rather than every hour (as with some antibiotic eye drops). The ointment creates a thin film that provides continuous antibiotic exposure.
The tradeoff? Temporary blurred vision after each application, since the ointment film affects how light enters your eye. Many patients prefer to apply it at bedtime for this reason.
There are several antibiotic eye medications available. Here's how Bacitracin/Polymyxin B compares:
Erythromycin is a single-antibiotic ointment from the macrolide class. It's commonly used for the same infections but has a narrower spectrum of coverage (mainly gram-positive bacteria). Bacitracin/Polymyxin B covers both gram-positive and gram-negative organisms, making it a broader-spectrum option.
Neosporin Ophthalmic adds a third antibiotic — Neomycin — for even broader coverage. However, Neomycin has a higher rate of causing allergic contact dermatitis (skin sensitization). Many doctors prefer the two-drug combination to avoid this risk.
Tobramycin is an aminoglycoside antibiotic available as both drops and ointment. It's particularly effective against Pseudomonas and other gram-negative bacteria. Drops are more convenient for daytime use (no blurred vision), but ointment provides longer contact time.
Ciprofloxacin is a fluoroquinolone antibiotic with very broad coverage. It's often reserved for more serious infections like corneal ulcers. Bacitracin/Polymyxin B is typically preferred for routine conjunctivitis because it's well-tolerated and has decades of safe use.
For a full comparison of alternatives, see our guide on alternatives to Bacitracin/Polymyxin B.
Bacitracin/Polymyxin B is elegantly simple: two antibiotics that attack bacteria through completely different mechanisms, covering a broad range of organisms. Bacitracin breaks down the cell wall; Polymyxin B destroys the cell membrane. Together, bacteria have a very hard time surviving.
It's been a trusted treatment for bacterial eye infections for decades, and for good reason — it works well, it's generally well-tolerated, and it's affordable. If you have more questions about using this medication, check out our articles on side effects and drug interactions.
Having trouble finding Bacitracin/Polymyxin B at your pharmacy? Medfinder can help you locate pharmacies with it in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
